The Objective of This Study is to Evaluate the Perfomance of a Photorefraction Device for Screening Ametropia in Children. Eligible Participants Will Undergo Multiple Refractive Error Measurements, Visual Acuity and Strabismus Assessments During a Single Evaluation Visit.

NCT06882408 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2025-04-29

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the performance of a photorefraction screener in terms of sensibility, sensitivity and accuracy on children aged 3 to 8 y.o. The main objectives of the study are:

* Evaluate the performances of the device in comparison with the gold standard, i.e. a tabletop refractometer.
* Assess the agreement of the measures obtained with the device with those obtained with the gold standard.

Conditions

  • Ametropia
  • Myopia; Refractive Error
  • Myopia; Astigmatism

Interventions

DEVICE

Photorefraction device under investigation

Objective refraction measurement with and without cyclopegia

DEVICE

Comparator device, Tabletop auto-refractometer

Objective refraction measurement with and without cyclopegia

DEVICE

Comparator device, portable photorefraction device

Objective refraction measurement with and without cyclopegia

OTHER

Distance visual acuity assessments

Distance visual acuity is assessed with the refraction measures found by the device under investigation and the comparator device with and without cyclopegia.

OTHER

Subjective refraction and far visual acuity

Subjective refraction is assessed and far visual acuity is assessed with the found refraction measures

OTHER

Strabismus assessment

Strabismus is assessed with the refraction measures found by the device under investigation and the comparator device with and without cyclopegia.

Sponsors & Collaborators

  • Essilor International

    lead INDUSTRY

Principal Investigators

  • Aranaud Sauer, MD, PhD, FEBO · Hôpital Civil de Strasbourg

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
8 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-30
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06882408 on ClinicalTrials.gov